United States Preventative Services Task Force Receives Proposed Changes Concerning “Breast Cancer: Medications for Risk Reduction”
Created in 1984, the United States Preventative Services Task Force (USPSTF) is an independent, volunteer panel of national experts in prevention and evidence-based medicine. The Task Force works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services such as screenings, counseling services, and preventive medications. All USPSTF recommendations are published on the Task Force’s Web site and/or in a peer-reviewed journal.
Seattle-based Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced this week that it has provided suggested changes to the draft recommendation of the United States Preventative Services Task Force (USPSTF) concerning “Breast Cancer: Medications for Risk Reduction.” The public comment period ends February 11, 2019, and the finalized USPSTF recommendations will become available in July 2019.
Atossa Genetics has proposed that the USPSTF recommendations include the following additional guidance:
- Mammographic breast density (MBD) provides the only patient level, biology-based assessment that is predictive of future breast cancer and it is modifiable. All women undergoing mammography should be informed of their breast density and its relationship to breast cancer incidence, risk, and mammographic sensitivity.
- Tamoxifen, but not raloxifene or aromatase inhibitors, is effective in reducing MBD and this reduction is associated with a reduced risk of estrogen-receptor positive breast cancer.
Dr. Steven Quay, Chairman, and CEO of Atossa Genetics stated, “Atossa is dedicated to the prevention of breast cancer through the use of mammography to identify women with MBD. There are over 3,400 peer-reviewed articles on the relationship between mammographic breast density and the risk of future breast cancer. Many states have laws that require that women be told their breast density at the time they have a mammogram, as well as the impact a high density has on both reducing the sensitivity of cancer detection and increased cancer incidence. Our recommended changes are based on a substantial, peer-reviewed foundation of research and, if accepted, should improve the utility of this widely used guidance. It is our hope that when this recommendation is updated in the future, Atossa’s proprietary Endoxifen, the active metabolite of tamoxifen, will be the leading approach to reduce breast density.”